Physician profile
Pradeep Kumar
NPI 1164424024
$2,332.52
in general payments reported to CMS, 2019-2025
19 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $132 · 2022: $72.54 · 2023: $153 · 2024: $284 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205 · Travel and Lodging: $658 · Education: $48.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.08 |
| Travel and Lodging | $657.71 |
| Education | $48.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,010.54 | 2025 | General - Therapies |
| Abbvie INC. | $269.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.50 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $192.55 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.48 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $91.67 | 2022-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $55.79 | 2019-2020 | |
| Celltrion USA INC. | $48.82 | 2024 | Zymfentra |
| Lilly USA, LLC | $44.55 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $40.88 | 2024 | |
| Vivus LLC | $36.57 | 2025 | Pancreaze, Qsymia |
| Phathom Pharmaceuticals, INC. | $22.49 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $22.09 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.08 | 2025 | Acanya |
| Ethicon US, LLC | $19.12 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $18.61 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $17.27 | 2022 | |
| Pfizer INC. | $15.43 | 2019 | |
| Shionogi INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.